Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes tardive dyskinesia: Not improved to a clinically important extent compared with other treatments (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Global impression: 2. Given medication during 12 months to three years · patients with schizophrenia and severe mental illness
INDIVIDUAL PSYCHODYNAMIC PSYCHOTHERAPY may leads to lower global impression: 2. Given medication during 12 months to three years compared with MEDICATION (low certainty).
2 findings from 1 review
Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months) · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence to antipsychotic medication: discontinued medication · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adherence to antipsychotic medication: discontinued medication compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
Benzodiazepines showed no clear difference in global state: need for additional medication ‐ medium termNumber of… compared with antihistamines plus antipsychotics (low certainty).
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in global state: need for additional medication ‐ + haloperidol ‐… compared with same enzodiazepines (low certainty).
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes global state: need for additional medication ‐ medium termNumber of… compared with placebo (very low certainty).
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
1 finding from 1 review
Global state: need for additional medication ‐ medium term · psychosis‐induced aggression or agitation
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
1 finding from 1 review
Compliance with medication · people with severe mental disorders
COURT ORDERED OUTPATIENT COMMITMENT showed no clear difference in health service outcomes: 4. Compliance with medication by 11 to 12… compared with ENTIRELY VOLUNTARY CARE (low certainty).
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (EPSEs requiring medication ‐ medium term) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect (EPSEs… compared with perphenazine (very low certainty).
1 finding from 1 review
Adverse effects: Clinically important general adverse effect ‐ short term (EPSEs requiring medication) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect ‐ short… compared with risperidone (very low certainty).
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · patients with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in global state: needing additional medication (sedation with chloral… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (low certainty).
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · schizophrenia
1 finding from 1 review